Advertisement
Breyanzi (brexucabtagene autoleucel): A Deep Dive into This Revolutionary CAR T-Cell Therapy
Introduction:
Are you or a loved one facing the daunting challenge of large B-cell lymphoma (LBCL)? The landscape of cancer treatment is constantly evolving, and breakthroughs like Breyanzi (brexucabtagene autoleucel) offer a beacon of hope. This comprehensive guide delves into the intricacies of Breyanzi, exploring its mechanism of action, clinical trials, efficacy, side effects, and future potential. We'll provide you with the information you need to understand this revolutionary CAR T-cell therapy and its role in combating this aggressive form of lymphoma. This post aims to be your definitive resource on Breyanzi, answering your questions and empowering you with knowledge.
What is Breyanzi (brexucabtagene autoleucel)?
Breyanzi is a groundbreaking chimeric antigen receptor (CAR) T-cell therapy specifically designed to target and eliminate cancerous B cells in patients with relapsed or refractory LBCL. Unlike traditional chemotherapy, which targets rapidly dividing cells indiscriminately, Breyanzi harnesses the power of the patient's own immune system. This personalized approach involves extracting T cells from the patient's blood, genetically modifying them to express a CAR that recognizes a specific antigen (CD19) found on the surface of B cells, including cancerous ones. These modified T cells are then expanded in the laboratory and reinfused into the patient, where they hunt down and destroy the malignant B cells.
Mechanism of Action: How Breyanzi Works
The magic behind Breyanzi lies in its precise targeting capability. The CD19 antigen is a protein found on the surface of most B cells, making it an ideal target for immunotherapy. The genetically modified T cells, equipped with the CD19-directed CAR, effectively recognize and bind to CD19-expressing B cells. Upon binding, the CAR triggers a cascade of intracellular signaling events, leading to the activation and proliferation of the T cells. This ultimately results in the destruction of the malignant B cells, while sparing healthy cells. This targeted approach minimizes off-target effects, leading to improved efficacy and reduced toxicity compared to traditional chemotherapeutic agents.
Clinical Trials and Efficacy: Demonstrating its Power
Breyanzi's approval was based on robust clinical trial data demonstrating its significant efficacy in patients with relapsed or refractory LBCL. The pivotal TRANSCEND NHL 001 trial showed impressive response rates, with a significant proportion of patients achieving complete remission. These results highlight Breyanzi's potential to transform the treatment landscape for patients with this aggressive form of lymphoma who have exhausted other treatment options. Ongoing research continues to explore the long-term efficacy and durability of response. Furthermore, studies are investigating potential combinations with other therapies to further enhance its effectiveness.
Side Effects and Management: Addressing Potential Risks
While Breyanzi offers significant therapeutic benefits, it is essential to be aware of the potential side effects. Like other CAR T-cell therapies, Breyanzi can induce cytokine release syndrome (CRS) and neurotoxicity. CRS is characterized by a systemic inflammatory response, while neurotoxicity can manifest as neurological symptoms ranging from mild cognitive impairment to severe encephalopathy. However, these side effects are typically manageable with supportive care, including medications to mitigate inflammation and neurological symptoms. Close monitoring and prompt intervention are crucial in managing these potential complications.
Breyanzi vs. Other CAR T-Cell Therapies: A Comparative Analysis
Several CAR T-cell therapies are available for treating LBCL, each with its unique characteristics and advantages. Comparing Breyanzi to other options requires a thorough evaluation of factors like efficacy, toxicity profiles, and patient selection criteria. For example, Breyanzi's efficacy profile is highly competitive, offering similar or superior response rates in certain patient populations. Understanding the nuances of each therapy is essential for selecting the most appropriate treatment strategy for an individual patient. Consultation with an experienced oncologist is critical in this decision-making process.
Future Directions and Ongoing Research: Looking Ahead
The field of CAR T-cell therapy is rapidly advancing, with ongoing research aimed at optimizing existing therapies and developing novel approaches. Future research on Breyanzi may focus on improving its efficacy, reducing toxicity, and expanding its application to other types of lymphoma and cancers. Researchers are also exploring ways to enhance the persistence and longevity of CAR T cells to achieve more durable responses. These advancements hold significant promise for improving the lives of patients with hematological malignancies.
Conclusion:
Breyanzi represents a remarkable advancement in the treatment of relapsed or refractory large B-cell lymphoma. Its targeted approach, robust efficacy data, and potential for long-term remission provide new hope for patients. While the potential for side effects must be carefully considered, effective management strategies are available. Further research and development promise even greater improvements in the future, solidifying Breyanzi’s position as a transformative therapy in the fight against cancer.
Article Outline:
Title: Breyanzi: A Comprehensive Guide to this Revolutionary CAR T-Cell Therapy
Introduction: Hooking the reader, overview of the article's content.
Chapter 1: What is Breyanzi? Definition, mechanism of action, target antigen (CD19).
Chapter 2: Clinical Trials and Efficacy: Review of pivotal trials, response rates, and overall survival data.
Chapter 3: Side Effects and Management: Discussion of CRS, neurotoxicity, and management strategies.
Chapter 4: Breyanzi vs. Other CAR T-Cell Therapies: Comparative analysis of similar treatments.
Chapter 5: Future Directions and Ongoing Research: Exploration of ongoing research and future potential.
Conclusion: Summarizing key points and emphasizing the importance of Breyanzi.
FAQs: Addressing common questions about Breyanzi.
Related Articles: List of related articles with brief descriptions.
(Each chapter would then be expanded upon, providing detailed information as described above.)
FAQs:
1. What type of cancer does Breyanzi treat? Breyanzi treats relapsed or refractory large B-cell lymphoma (LBCL).
2. How does Breyanzi work? It uses genetically modified T cells to target and destroy cancerous B cells expressing the CD19 antigen.
3. What are the common side effects of Breyanzi? Cytokine release syndrome (CRS) and neurotoxicity are the most common.
4. How is CRS and neurotoxicity managed? Supportive care, including medications to reduce inflammation and manage neurological symptoms.
5. Is Breyanzi suitable for all patients with LBCL? No, it's primarily for patients who have relapsed or are refractory to other treatments.
6. How long does Breyanzi treatment last? The treatment process includes several steps, from cell collection to infusion, spanning several weeks.
7. What is the success rate of Breyanzi? Clinical trials have shown significant response rates, but individual results vary.
8. What are the long-term effects of Breyanzi? Long-term studies are ongoing to determine the long-term effects.
9. Where can I find more information about Breyanzi clinical trials? ClinicalTrials.gov is a good resource to find ongoing and completed clinical trials.
Related Articles:
1. CAR T-Cell Therapy: A Revolutionary Approach to Cancer Treatment: An overview of CAR T-cell therapy technology and its applications.
2. Cytokine Release Syndrome (CRS) in CAR T-Cell Therapy: A detailed explanation of CRS, its management, and potential complications.
3. Neurotoxicity in CAR T-Cell Therapy: A deep dive into the neurological side effects of CAR T-cell therapy and mitigation strategies.
4. Large B-Cell Lymphoma: Diagnosis, Treatment, and Prognosis: A comprehensive guide to LBCL, including various treatment options.
5. Relapsed and Refractory Lymphoma: Treatment Challenges and Advances: An exploration of the challenges in treating relapsed and refractory lymphoma.
6. Immunotherapy in Cancer Treatment: Principles and Applications: A broader perspective on immunotherapy and its role in cancer treatment.
7. Personalized Medicine in Oncology: Tailoring Cancer Treatment to the Individual: An overview of personalized medicine and its application in cancer treatment.
8. The Future of Cancer Treatment: Emerging Therapies and Technologies: Exploring cutting-edge technologies and approaches in cancer research and treatment.
9. Navigating the Healthcare System with a Cancer Diagnosis: Resources and Support: Guidance for patients and families facing a cancer diagnosis.
| breyanzi pi: Lippincott Illustrated Reviews: Pharmacology Karen Whalen, 2022-08-18 Students’ favorite review resource for studying the essentials of medical pharmacology, Lippincott® Illustrated Reviews: Pharmacology, 8th Edition, presents up-to-date drug information in an accessible format ideal for effective review. Part of the popular Lippincott® Illustrated Reviews series, this concise resource features clear writing and hundreds of illustrations that break down complex pharmacological information, so it is understandable and accessible. Sequential images present mechanisms of action and focus on showing rather than telling students how drugs work, and review questions with answers deliver powerful, practical exam preparation. |
| breyanzi pi: Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy , 2018-11-21 Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. - Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research - Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms - Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment |
| breyanzi pi: Anesthesia for Oncological Surgery Jeffrey Huang, |
| breyanzi pi: Upper Tract Urothelial Carcinoma Shahrokh F. Shariat, Evanguelos Xylinas, 2014-09-13 Upper Tract Urothelial Carcinoma represents the first book of its kind to be dedicated solely to UTUC. It's aim is to improve understanding and eventually care of a disease that is greatly understudied and underappreciated, yet commonly dealt with by many medical and urologic oncologists. The volume features new data regarding genetic susceptibility, gene expression studies and causative factors; contemporary concepts and controversies regarding diagnosis and staging of UTUC; prediction tools and their value in treatment decisions within each disease stage and patient selection and treatment options such as endoscopic management, distal ureterectomy, radical nephroureterectomy and chemotherapy. Up-to-date information regarding boundaries of surgical resection, indication and extent of lymphadenectomy is covered as well as the role of perioperative/neoadjuvant chemotherapy in patients with high-risk UTUC. Upper Tract Urothelial Carcinoma will be of great value to all Urologists, Medical Oncologists and fellows in Urologic Oncology as well as upper level residents in training in Urology and Medical Oncology. |
| breyanzi pi: Curing Genetic Diseases through Genome Reprogramming , 2021-06-24 Curing Genetic Diseases through Genome Reprogramming, Volume 182 captures an historic moment in the field of gene therapy—the dawn of a new age in which the dream of curing genetic diseases has become realizable. The volume presents the most clinically advanced gene therapy and genome editing approaches for the treatment of genetic diseases in specific organs, including difficult therapeutic targets, futuristic ideas of genetic interventions, and large scale human genome repair. An initial chapter addresses the complex ethical aspects involved in the very idea of modifying the human genome. - Provides a comprehensive view of gene therapy and genome editing technologies, including epigenetic editing - Describes the state-of-the-art and future directions for the treatment of genetic diseases, also considering economical aspects - Presents chapters that each give a thorough review of a specific disease, target organ or visionary approach, including ethical considerations |
| breyanzi pi: Recent Advances On Mesenchymal Stromal Cells Applications For Cancer Therapy Abdelkrim Hmadcha, Virgínea De Araújo Farias, Rasime Kalkan, Rajaa El Bekay, Tarik Smani, 2022-12-29 |
| breyanzi pi: HER2-Positive Breast Cancer Sara Hurvitz, Kelly McCann, 2018-07-26 Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies. |
| breyanzi pi: Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk Michael J. Klepper, Barton Cobert, 2010-09-15 Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk was selected for The First Clinical Research Bookshelf - Essential reading for clinical research professionals by the Journal of Clinical Research Best Practices. Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk provides drug safety/pharmacovogilance professionals, pharmaceutical and clinical research scientists, statisticians, programmers, medical writers, and technicians with an accessible, practical framework for the analysis, summary and interpretation of drug safety data. The only guide of its kind, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is an invaluable reference for pre- and post-marketing risk assessment. With decades of pharmaceutical research and drug safety expertise, authors Dr. Klepper and Dr. Cobert discuss how quality planning, safety training, and data standardization result in significant cost, time, and resource savings. Through illustrative, step-by-step instruction, Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk is the definitive guide to drug safety data analysis and reporting. Key features include: * Step-by-step instruction on how to analyze, summarize and interpret safety data for mandatory governmental safety reports * Pragmatic tips...and mistakes to avoid * Simple explanations of what safety data are collected, and what the data mean * Practical approaches to determining a drug effect and understanding its clinical significance * Guidance for determining risk throughout the lifecycle of a drug, biologic or nutraceutical * Examples of user-friendly data displays that enhance safety signal identification * Ways to improve data quality and reduce the time, resources and costs involved in mandatory safety reporting * Relevant material for the required training of drug safety/pharmacovigilance professionals * SPECIAL FEATURE: Actual examples of an Integrated Analysis of Safety (IAS) -used in the preparation of the Integrated Summary of Safety (ISS) and the Summary of Clinical Safety (SCS) reports -, and the Periodic Safety Update Report (PSUR) |
| breyanzi pi: Lipid Nanocarriers for Drug Targeting Alexandru Mihai Grumezescu, 2018-04-16 Lipid Nanocarriers for Drug Targeting presents recent advances in the area of lipid nanocarriers. The book focuses on cationic lipid nanocarriers, solid lipid nanocarriers, liposomes, thermosensitive vesicles, and cubosomes, with applications in phototherapy, cosmetic and others. As the first book related to lipid nanocarriers and their direct implication in pharmaceutical nanotechnology, this important reference resource is ideal for biomaterials scientists and those working in the medical and pharmaceutical industries that want to learn more on how lipids can be used to create more effective drug delivery systems. - Highlights the most commonly used types of lipid nanocarriers and explains how they are applied in pharmacy - Shows how lipid nanocarriers are used in different types of treatment, including oral medicine, skin repair and cancer treatment - Assesses the pros and cons of using different lipid nanocarriers for different therapies |
| breyanzi pi: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| breyanzi pi: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| breyanzi pi: The Immunotype Breakthrough Heather Moday, 2021-12-21 A respected immunologist, allergist, and functional medicine doctor breaks down the latest science on immunity, offering “the most important guide available” (Mark Hyman, MD) to balancing your system for optimal health and longevity. To most of us, the immune system is seemingly unknowable—it's an invisible, complex network of cells, receptors, and messengers, and there's no standard way to see if it's functioning as it should. Yet in spite of this, it affects every aspect of our health, influencing (and sometimes even causing) nearly every disease known to humanity. Much has been made about “boosting” immunity, but what exactly does that mean, and what if boosting isn't really what your unique system needs? In The Immunotype Breakthrough, Dr. Heather Moday explains that for most, immune system balance is key. Drawing on a wealth of cutting edge research and fascinating case studies, Dr. Moday explains that the immune system is fluid and significantly influenced by our behaviors, diet, habits, and environment. She identifies four primary Immunotypes—Smoldering, Weak, Hyperactive, and Misguided—that underlie the immune imbalances that commonly lead to disease, chronic inflammation, infection, allergies, and autoimmunity. By identifying your personal immunotype—where you fall on this immunity spectrum—you can intervene by making focused, individualized, natural lifestyle changes to ensure it functions optimally Featuring engaging and accessible science, practical and customizable takeaways, and interactive quizzes to help you zero in on your specific needs, The Immunotype Breakthrough is a revolutionary program for creating an individualized lifestyle and diet that will lead to immune resilience, vitality, and longevity. |
| breyanzi pi: Protein-protein Recognition Colin Kleanthous, 2000 The purpose of Protein-Protein Recognition is to bring together concepts and systems pertaining to protein-protein interactions in a single unifying volume. In the light of the information from the genome sequencing projects and the increase in structural information it is an opportune time totry to make generalizations about how and why proteins form complexes with each other. The emphasis of the book is on heteromeric complexes (complexes in which each of the components can exist in an unbound state) and will use well-studied model systems to explain the processes of formingcomplexes. After an introductory section on the kinetics, thermodynamics, analysis, and classification of protein-protein interactions, weak, intermediate, and high affinity complexes are dealt with in turn. Weak affinity complexes are represented by electron transfer proteins and integrincomplexes. Anti-lysozyme antibodies, the MHC proteins and their interactions with T-cell receptors, and the protein interactions of eukaryotic signal transduction are the systems used to explain complexes with intermediate affinities. Finally, tight binding complexes are represented by theinteraction of protein inhibitors with serine proteases and by nuclease inhibitor complexes. Throughout the chapters common themes are the technologies which have had the greatest impact, how specificity is determined, how complexes are stabilized, and medical and industrial applications. |
| breyanzi pi: Modern Approaches in Drug Discovery , 2018-10-31 Modern Approaches in Drug Discovery, Volume 611, the latest release in the Methods in Enzymology series, highlights new advances in the field, with this new volume presenting interesting chapters on topics such as Target Identification and Validation, Cell Painting/High Content Imaging, Target ID using chemical probes, Mining the microbiome for targets, Data driven approaches for diversity and drug-likeness, Affinity-based screening, Fragment screening (X-ray), Array-based approaches, Hit-to-lead: assessment and improvement of drug-like properties, Hit assessment and prioritization, Lead Optimization: fine tuning and risk mitigation, and more. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the Methods in Enzymology series - Updated release includes the latest information on the Intrinsically Disordered Proteins |
| breyanzi pi: Advanced Drug Delivery Systems in the Management of Cancer Kamal Dua, Meenu Mehta, Terezinha de Jesus Andreoli Pinto, Lisa G. Pont, Kylie A. Williams, Michael Rathbone, 2021-06-24 Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer. - Presents an overview of the recent perspectives and challenges within the management and diagnosis of cancer - Provides insights into how advanced drug delivery systems can effectively be used in the management of a wide range of cancers - Includes up-to-date information on diagnostic methods and treatment strategies using controlled drug delivery systems |
| breyanzi pi: Ex Vivo Cell Therapy Klaus Schindhelm, Robert Nordon, 1999 R.E. Nordon and K. Schindhelm, Introduction. -- L. Robb, A.G. Elefanty, and C.G. Begley, Transcriptional Control of Hematopoieses. -- R. Starr and N.A. Nicola, Cell Signaling by Hemopoietic Growth Factor Receptors. -- P.J. Simmons, D.N. Haylock, and J.-P. Lévesque, Influence of Cytokines and Adhesion Molecules on Hematopoietic Stem Cell Development. -- P.A. Rowlings, Allogeneic Hematopoietic Stem Cell Transplantation. -- U. Hahn and L.B. To, Autologous Stem Cell Transplantation. -- M.R. Vowels, Cord Blood Stem Cell Transplantation. -- S.R. Riddell, E.H. Warren, D. Lewinsohn, C. Yee, and P.D. Greenberg, Reconstitution of Immunity by Adoptive Immunotherapy with T Cells. -- L.Q. Sun, M. Miller, and G. Symonds, Exogenous Gene Transfer into Lymphoid and Hematopoietic Progenitor Cells. -- C. Dowding, T. Leemhuis, A. Jakubowski, and C. Reading, Process Development for Ex Vivo Cell Therapy. -- R.E. Nordon and K. Schindhelm, Cell Separation. -- P.W. Zandstra, C.J. Eaves, and J.M. Piret, Environ ... |
| breyanzi pi: Bone Tissue Engineering Jeffrey O. Hollinger, Thomas A. Einhorn, Bruce Doll, Charles Sfeir, 2004-10-14 Focusing on bone biology, Bone Tissue Engineering integrates basic sciences with tissue engineering. It includes contributions from world-renowned researchers and clinicians who discuss key topics such as different models and approaches to bone tissue engineering, as well as exciting clinical applications for patients. Divided into four sections, t |
| breyanzi pi: Therapeutic Antibody Engineering William R Strohl, Lila M Strohl, 2012-10-16 The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. - Goes beyond the standard engineering issues covered by most books and delves into structure-function relationships - Integration of knowledge across all areas of antibody engineering, development, and marketing - Discusses how current and future genetic engineering of cell lines will pave the way for much higher productivity |
| breyanzi pi: Nucleic Acids as Gene Anticancer Drug Delivery Therapy Loutfy H. Madkour, 2019-08-27 Nucleic Acids as Gene Anticancer Drug Delivery Therapy highlights the most recent developments in cancer treatment using nucleic acids, nanoparticles and polymer nanoparticles for genomic nanocarriers as drug delivery, including promising opportunities for targeted and combination therapy. The development of a wide spectrum of nanoscale technologies is beginning to change the scientific landscape in terms of disease diagnosis, treatment, and prevention. This book presents the use of nanotechnology for medical applications, focusing on its use for anticancer drug delivery. Various intelligent drug delivery systems such as inorganic nanoparticles and polymer-based drug delivery are discussed. The use of smart drug delivery systems seems to be a promising approach for developing intelligent therapeutic systems for cancer immunotherapies and is discussed in detail along with nucleic acid-targeted drug delivery combination therapy for cancer. Nucleic Acids as Gene Anticancer Drug Delivery Therapy will be a useful reference for pharmaceutical scientists, pharmacologiests, and those involved in nanotechnology and cancer research. - Discusses intelligent drug delivery systems such as inorganic nanoparticles and polymer-based drug delivery - Contains a comprehensive comparison of various delivery systems, listing their advantages and limitations - Presents combination therapy as a new hope for enhancing current gene-based treatment efficacy |
| breyanzi pi: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| breyanzi pi: Polysaccharide Materials Kevin Edgar, Thomas Heinze, Charles Buchanan, 2009 Today we are experiencing a renaissance in the chemistry of polysaccharide materials. This is due in part to recognition of the importance of renewable-based materials in a society in which petroleum has become a much more expensive feedstock, with a cloudy future with respect to adequacy of supply. There are currently intense, global efforts to develop a biomass-based refinery process, intended to produce biofuel (ethanol or butanol being the top candidates) that will replace some or all of the petroleum-based fuel we now use. In parallel, scientists and non-scientists have become aware of the opportunities that this biofuel industry will create for biomass-based products. The utilization of waste from the biofuel process, along with the exploitation of the collection system for biomass that will serve the biofuel production process, to make other products from biomass, will create an unprecedented and revolutionary opportunity for the creation of integrated biorefineries. These biorefineries will have substantial resemblance to current petroleum refineries, in that they will convert a natural product (or more properly, products) into fuel by chemical transformations and separation processes, and simultaneously use co-products and main products as feedstocks for the production of more complex chemicals. In order to take advantage of the opportunities presented by a biorefinery-based economy, it is crucial that we develop new synthetic methods for polysaccharide derivatives, and new understanding of the structure-property-performance relationships of these versatile molecules. This symposium series book will describe new synthetic methods, novel polysaccharide derivatives, new applications of these derivatives in biomedicine and packaging applications, and numerous examples of the creation of new insight into the design of polysaccharide materials for performance. The articles in this symposium series book are good examples of the advances in polysaccharide chemistry being made in the current renaissance that will help to move us towards a biorefinery future. |
| breyanzi pi: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell Therapies Guido Moll, Martin Johannes Hoogduijn, James A. Ankrum, 2020-07-24 |
| breyanzi pi: Cancer Vaccines and Immunotherapy Peter L. Stern, Peter C. L. Beverley, Miles Carroll, 2000-08-17 Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments. |
| breyanzi pi: Cell Therapy Adrian Gee, 2009-09-18 Cell Therapy: cGMP Facilities and Manufacturing is the source for a complete discussion of facility design and operation with practical approaches to a variety of day-to-day activities, such as staff training and competency, cleaning procedures, and environmental monitoring. This in-depth book also includes detailed reviews of quality, the framework of regulations, and professional standards. It meets a previously unmet need for a thorough facility-focused resource, Cell Therapy: cGMP Facilities and Manufacturing will be an important addition to the cell therapy professional’s library. Additional topics in Cell Therapy: cGMP Facilities and Manufacturing...Standard operating procedures - Supply management - Facility equipment - Product manufacturing, review, release and administration - Facility master file. |
| breyanzi pi: Design of Nanostructures for Theranostics Applications Alexandru Mihai Grumezescu, 2017-11-30 Design of Nanostructures for Theranostics Applications focuses on the theranostics applications of nanostructures. In particular, multifunctional nanoparticles for diagnostics and treatment of different diseases, including those relating to the blood-brain barrier, are discussed in detail. Chapters explore different type of nanostructures, covering design, fabrication, functionalization and optimization, helping readers obtain the desired properties. Written by a diverse range of international academics, this book is a valuable reference resource for those working in both nanoscience and the pharmaceutical industry. - Explores how the design of a range of nanomaterials make them effective theranostic agents, including multifunctional core-shell nanostructures, mesoporous silica nanoparticles, and quantum dots - Shows how nanomaterials are used effectively for a range of diseases, including breast cancer, prostate cancer and neurological disorders - Assesses the pros and cons of using different nanomaterials for different types of treatment |
| breyanzi pi: Delivery and induction United States. Selective Service System, 1944 |
| breyanzi pi: Immune Hematology Jenny M. Despotovic, 2018-05-14 This text provides a concise yet comprehensive overview of the most common autoimmune cytopenias affecting adults and children. The book is divided into four sections, each of which focuses on a major autoimmune cytopenia. The first section features background, pathophysiology, presentation, evaluation, and treatment strategies for immune thrombocytopenia (ITP), the most common cause of antibody-mediated platelet destruction. The second section reviews common forms and treatment strategies for autoimmune hemolytic anemia (AIHA), including a chapter dedicated specifically to Evans Syndrome. The third section comprehensively reviews the pathophysiology, diagnosis and current management approaches to thrombotic thrombocytopenic purpura (TTP), a potentially life-threatening autoimmune syndrome. The book concludes with a final section on autoimmune neutropenia. Each section includes a review of common underlying systemic autoimmune conditions and immune deficiency syndromes that can accompany or cause autoimmune cytopenias. Written by experts in each content area, Immune Hematology: Diagnosis and Management of Autoimmune Cytopenias is a valuable resource for clinicians and professionals who treat patients afflicted with autoimmune cytopenias, including primary care providers, hematologist/oncologists, immunologists, among others. |
| breyanzi pi: Engineering Drug Delivery Systems Ali Seyfoddin, Seyedehsara Masoomi Dezfooli, Carol Ann Greene, 2019-11-15 Engineering Drug Delivery Systems is an essential resource on a variety of biomaterials engineering approaches for creating drug delivery systems that have market and therapeutic potential. The book comprehensively discusses recent advances in the fields of biomaterials and biomedical sciences in relation to drug delivery. Chapters provide a detailed introduction to various engineering approaches in designing drug delivery systems, delve into the engineering of body functions, cover the selection, design and evaluation of biomaterials, and discuss the engineering of colloids as drug carriers. The book's final chapters address the engineering of implantable drug delivery systems and advances in drug delivery technology. This book is an invaluable resource for drug delivery, materials scientists and bioengineers within the pharmaceutical industry. - Examines the properties and synthesis of biomaterials for successful drug delivery - Discusses the important connection between drug delivery and tissue engineering - Includes techniques and approaches applicable to a wide range of users - Reviews innovative technologies in drug delivery systems such as 3-D printed devices for drug delivery |
| breyanzi pi: Nanoparticles in Pharmacotherapy Alexandru Mihai Grumezescu, 2019-04-10 Nanoparticles in Pharmacotherapy explores the most recent findings on how nanoparticles are used in pharmacotherapy, starting with their synthesis, characterization and current or potential uses. This book is a valuable resource of recent scientific progress that includes the most cutting-edge applications of nanoparticles in pharmacotherapy. It is ideal for researchers, medical doctors and those in academia. |
| breyanzi pi: Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents Manju Rawat Singh, Deependra Singh, Jagat Kanwar, Nagendra Singh Chauhan, 2020-04-07 Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents provides sound data on the utility of biological and plant-based drugs and describes challenges faced in all aspects offering indispensable strategies to use in the development of bioactive medicines. Bioactive based medications are commonly used throughout the world and have been recognized by physicians and patients for their therapeutic efficacy. Bioactive formulations, including their subordinates and analogs, address 50% of all medicines in clinical practice. Novel bioactive medicine transporters can cure many disorders by both spatial and transitory approaches and have various justifications in medicinal potential. This book presents information on the utility of natural, plant, animal and bioengineered bioactive materials. It is a fundamental source of information and data for pharmacognosists, pharmaceutical analysts, drug transport scientists and pharmacologists working in bioactive medications. - Advances information on various bioactive based medications, their sources, clinical consequences and transport strategies - Illustrates diverse transport systems for bioactives and derivatives, novel techniques for formulations, targeting strategies and fundamental qualities of developed bioactive carriers, and their safety concerns and standardization - Discusses distinctive transport systems, stability, upgraded dissolvability, and enhanced bioavailability of bioactives |
| breyanzi pi: Junior Chemist National Learning Corporation, 2019-02 The Junior Chemist Passbook(R) prepares you for your test by allowing you to take practice exams in the subjects you need to study. |
| breyanzi pi: Biology of Aging Alvaro Macieira-Coelho, 2002-10-21 The survival of the human species has improved significantly in modern times. During the last century, the mean survival of human populations in developed countries has increased more than during the preceding 5000 years. This improvement in survival was accompanied by an increase in the number of active years. In other words, the increase in mean life span was accompanied by an increase in health span. This is now accentuated by progress in medicine reducing the impact of physiologic events such as menopause and of patho logical processes such as atherosclerosis. Up to now,research on aging, whether theoretical or experimental, has not contributed to improvement in human survival. Actually, there is a striking contrast between these significant modifications in survival and the present knowledge of the mechanisms of human aging. Revealed by this state of affairs are the profound disagreements between gerontologists in regard to the way oflooking at the aging process. The definition of aging itself is difficult to begin with because of the variability of how it occurs in different organisms. |
| breyanzi pi: Antibody-antigen Complexes Eduardo Padlan, 1994 |
| breyanzi pi: Endoplasmic Reticulum Stress in Health and Disease Patrizia Agostinis, Samali Afshin, 2012-08-13 The Endoplasmic Reticulum (ER) is an organelle with extraordinary signaling and homeostatic functions. It is the organelle responsible for protein folding, maturation, quality control and trafficking of proteins destined for the plasma membrane or for secretion into the extracellular environment. Failure, overloading or malfunctioning of any of the signaling or quality control mechanisms occurring in the ER may provoke a stress condition known as ‘ER stress’. Accumulating evidence indicates that ER stress may dramatically perturb interactions between the cell and its environment, and contribute to the development of human diseases, ranging from metabolic diseases and cancer to neurodegenerative diseases, or impact therapeutic outcome. This book primarily focuses on the pathophysiology of ER stress. It introduces the molecular bases of ER stress, the emerging relevance of the ER-mitochondria cross-talk, the signaling pathways engaged and cellular responses to ER stress, including the adaptive Unfolded Protein Response (UPR), autophagy as well as cell death. Next the book addresses the role of ER stress in physiology and in the etiology of relevant pathological conditions, like carcinogenesis and inflammation, neurodegeneration and metabolic disease. The last chapter describes how ER stress pathways can be targeted for therapeutic benefit. Altogether, this book will provide the reader with an exhaustive view of ER stress biology and the latest insights in the role of ER stress in relevant human diseases. |
| breyanzi pi: Improving Medicare Adam K. Brooks, 2011 The Medicare program enables millions of beneficiaries to obtain health care services; however, lacks many of the essential elements of a high-quality, high-value and efficient health system. Program spending and utilisation have increased substantially, without corresponding improvements in beneficiaries' health. This new and important book describes the need for Medicare to move away from payment policies that encourage service volume and are indifferent to quality and toward policies that promote better value for Medicare and its beneficiaries. |
| breyanzi pi: The Development of Human Gene Therapy Theodore Friedmann, 1999 The idea of human gene therapy was accepted by the medical community and society at large long before believable clinical benefits began to emerge. In this book, some of the fields most distinguished contributors chronicle the evolution of this momentous direction for medicine, illustrating how imaginative concepts shaped the development of technologies and brought the daring new idea to its current position of imminent practical success. This is a book designed to endure as clinical advances accumulate, a clear-eyed work of reference that will anchor the further development of this revolution in therapy. It is an essential addition to libraries of clinical medicine, biotechnology, and public policy, and a resource that no laboratory investigator with an interest in the biology of gene transfer should be without. |
